Want to see TSE:ARCH full AI Analyst Report?

Arch Biopartners (ARCH) Price & Analysis

50 Followers

ARCH Stock Chart & Stats

C$0.87

-C$0.02(-2.30%)

At close: Jul 27 4:00 PM EDT

C$0.87

-C$0.02(-2.30%)

Day’s Range― - ―

52-Week RangeC$0.39 - C$1.72

Previous CloseN/A

Volume14.22K

Average Volume (3M)43.97K

Market Cap

C$76.09M

Enterprise ValueC$36.94M

Total Cash (Recent Filing)C$436.76K

Total Debt (Recent Filing)C$2.73M

Price to Earnings (P/E)―

Beta1.11

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding67,933,290

10 Day Avg. Volume31,059

30 Day Avg. Volume43,967

Financial Highlights & Ratios

PEG Ratio0.88

Price to Book (P/B)-21.63

Price to Sales (P/S)0.00

P/FCF Ratio-53.01

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.16

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Platform-based Antibody DiscoveryOwning a discovery platform and monoclonal antibody pipeline creates a durable competitive advantage: it supports multiple program candidates, enables licensing or co-development deals, and concentrates R&D know‑how. This reduces single‑asset binary risk and improves long-term partner interest and deal optionality.

Debt ReductionLower nominal debt materially reduces near-term refinancing pressure and interest burden for a small clinical-stage company. This improvement strengthens the balance sheet cushion, lengthens runway versus prior periods and modestly lowers insolvency risk while management pursues development milestones.

Narrowing Losses And Improved Cash BurnConsistent narrowing of net losses and reduced operating cash burn indicate better cost discipline or more efficient R&D spend. For a pre-revenue biotech, this trend extends runway, reduces frequency/size of dilutive financings, and signals management can stretch capital toward value-driving clinical readouts or partner discussions.

Bears Say

No Current RevenueZero revenue is structural for a clinical-stage biotech until approvals or licensing monetization; it forces reliance on external capital or milestone-bearing partnerships. This limits self-funding, increases dilution risk, and makes long-term program advancement contingent on successful financing or partner deals.

Negative Equity And Tiny Asset BaseNegative shareholders' equity and minimal assets create a fragile capital structure, elevating insolvency and creditor risk during prolonged development cycles. It constrains borrowing capacity, weakens negotiation leverage with partners, and implies limited internal resources to absorb setbacks.

Very Small Operating ScaleA tiny team limits internal execution bandwidth for simultaneous trials, regulatory interactions and commercialization planning. Heavy reliance on external partners for funding and operations raises execution and timeline risk, and success depends on securing deals rather than internal commercial traction.

Arch Biopartners News

Arch Biopartners publishes data linking cytokine IL-32 to inflammation, DKD

Arch Biopartners (ACHFF) announced that a scientific team led by Dr. Justin Chun at the University of Calgary...

6M ago

Arch Biopartners appoints Patrick Vink as chairman of the board

Arch Biopartners (ACHFF) announced the appointment of Dr. Patrick Vink as Chairman of the Company’s Board of Directors,...

7M ago

Arch granted ethics approval for St. Michaels participation in Phase II trial

Arch Biopartners (ACHFF) announced that the University Health Network Research Ethics Board has granted ethics approval for St....

8M ago

Arch Biopartners’ LSALT Peptide Study: A Promising Step in AKI Prevention

Arch Biopartners (($TSE:ARCH)) announced an update on their ongoing clinical study. Arch Biopartners is conducting a Phase 2...

10M ago

ARCH

ARCH FAQ

What was Arch Biopartners’s price range in the past 12 months?

Arch Biopartners lowest stock price was C$0.39 and its highest was C$1.72 in the past 12 months.

What is Arch Biopartners’s market cap?

Arch Biopartners’s market cap is C$76.09M.

When is Arch Biopartners’s upcoming earnings report date?

Arch Biopartners’s upcoming earnings report date is Aug 27, 2026 which is in 4 days.

How were Arch Biopartners’s earnings last quarter?

Arch Biopartners released its earnings results on Jun 02, 2026. The company reported -C$0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.008.

Is Arch Biopartners overvalued?

According to Wall Street analysts Arch Biopartners’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Arch Biopartners pay dividends?

Arch Biopartners does not currently pay dividends.

What is Arch Biopartners’s EPS estimate?

Arch Biopartners’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Arch Biopartners have?

Arch Biopartners has 67,933,290 shares outstanding.

What happened to Arch Biopartners’s price movement after its last earnings report?

Arch Biopartners reported an EPS of -C$0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.769%.

Which hedge fund is a major shareholder of Arch Biopartners?

Currently, no hedge funds are holding shares in TSE:ARCH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Arch Biopartners Stock Smart Score

Neutral

Insider Transactions

Sold Shares

Worth C$486.2K over
the Last 3 Months

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-15.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arch Biopartners

Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.